… treatment with the maximal tolerated dose of valsartan did not exhibit a superior effect on
post-MI LV remodelling compared with low-dose treatment … this study is the use of beta-blockers …

… use of high-dose beta-blocker appears harmful for patients who present in HF. The American
College of Cardiology (ACC)/American Heart … Therefore, valsartan, in the dosages used in …

… recommend the use of neurohormonal blocking agents in HF patients [2, 3] … VALsartan In
Acute myocardial iNfarcTion (VALIANT) trial that evaluated the effects of captopril and valsartan…

… used to stain 4-µm-thick paraffin sections of infarct core samples. Picrosirius red staining of
the infarct core and the remote zone was used … of post-myocardial infarction and heart failure …

… of the patients to either ramipril or sacubitril/valsartan our … and sacubitril valsartan in relation
to use of MRA Patients were … these patients were as expected at higher risk than patients not …

… and captopril group as compared to captopril and valsartan … patients with LVEF ≤40%
reduces the risk of cardiovascular events. HF guidelines recommend the use of ARBs in patients …

… valsartan (ARB), which is used as an alternative to or alongside ACEi and ARB in patients
with symptomatic chronic heart failure … recommend sacubitril/valsartan as a replacement for an …

… There is a lack of studies comparing the risk of cardio-cerebrovascular disease between …
infarction (MI), heart failure (HF), and cerebrovascular disease with the use of valsartan, losartan…

… (LV) remodeling post myocardial infarction (post-MI) [ 1 , 2 ], … (ARB) in the treatment of
heart failure with reduced ejection … Therefore, the application of Sac/Val in patients with AAMI …

… the mainstays of treatment for patients with LVSD after myocardial infarction (46). Whether
sacubitril and valsartan can be used early in patients with heart failure after acute myocardial …